Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10964997 | Vaccine | 2014 | 6 Pages |
Abstract
Vaccination strategies for coronaviruses have involved live attenuated virus, recombinant viruses, non-replicative virus-like particles expressing coronavirus proteins or DNA plasmids expressing coronavirus genes. None of these strategies has progressed to an approved human coronavirus vaccine in the ten years since SARS-CoV emerged. Here we describe a novel method for generating MERS-CoV and SARS-CoV full-length spike nanoparticles, which in combination with adjuvants are able to produce high titer antibodies in mice.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Christopher M. Coleman, Ye V. Liu, Haiyan Mu, Justin K. Taylor, Michael Massare, David C. Flyer, Gregory M. Glenn, Gale E. Smith, Matthew B. Frieman,